Neurological Research最新文献

{"title":"Letter to Editor: regarding the article \"efficacy and safety of hematopoietic and mesenchymal stem cells in multiple sclerosis: a meta-analysis\".","authors":"Murat Kürtüncü","doi":"10.1080/01616412.2025.2534518","DOIUrl":"https://doi.org/10.1080/01616412.2025.2534518","url":null,"abstract":"","PeriodicalId":19131,"journal":{"name":"Neurological Research","volume":" ","pages":"1-2"},"PeriodicalIF":1.7,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144708258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploration of the relationship between autoimmune neurologic diseases and mental disorders: evidence from Mendelian randomization study.","authors":"Yu Shen, WenWen Xiang, Qun Xiong, Si Luo, Hao Chen, Ziwei Song, Yusen Qiu, Lijun Pang, Daojun Hong","doi":"10.1080/01616412.2025.2534082","DOIUrl":"https://doi.org/10.1080/01616412.2025.2534082","url":null,"abstract":"<p><strong>Introduction: </strong>Traditional epidemiologic studies suggest that autoimmune neurologic diseases may be associated with mental disorders (MDs). We used Mendelian randomization (MR) studies to explore the causal relationship between autoimmune neurologic diseases and MDs from the genetic perspective.</p><p><strong>Methods: </strong>In our study, autoimmune neurologic diseases include multiple sclerosis (MS), neuromyelitis optica (NMO), and myasthenia gravis (MG); MDs include anxiety, major depressive disorder (MDD), attention deficit/hyperactivity disorder (ADHD), schizophrenia, and bipolar affective disorder (BIP). A two-sample MR approach was used to explore causal relationships. The inverse variance weighted (IVW) method was the primary method for MR analysis. In addition, we included all MG datasets for meta-analysis after MR analysis with ADHD.</p><p><strong>Results: </strong>Regarding the causal effects of MDs on autoimmune neurologic diseases, our analyses revealed a causal relationship between genetically predicted ADHD and MG (OR 2.250; 95% CI 1.267-3.998; <i>p</i> = 0.006), and no potential genetic causal relationships were found between the other diseases. However, according to the MR‒Egger analysis, there was no indication of directional pleiotropy. For the causal effects of autoimmune neurologic diseases on MDs, no potential genetic causal relationships were identified between any of the diseases. We performed a meta-analysis for MG and ADHD, there was no significant genetic causal relationship between ADHD and MG (OR 1.30 (95% CI 0.95-1.79); <i>p</i> = 0.10).</p><p><strong>Conclusion: </strong>This study revealed that there was no genetic mechanism linking autoimmune neurologic diseases and MDs to each other. These findings provide a foundation for the prevention and treatment of comorbid conditions in clinical research.</p>","PeriodicalId":19131,"journal":{"name":"Neurological Research","volume":" ","pages":"1-11"},"PeriodicalIF":1.7,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144708257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of tramadol and levetiracetam in preventing peridural fibrosis after laminectomy in rats.","authors":"Ibrahim Umud Bulut, Ulas Yuksel, Bahar Kartal, Asli Fahriye Ceylan, Mustafa Ilker Karagedik, Alemiddin Ozdemir, Mustafa Ogden, Bulent Bakar","doi":"10.1080/01616412.2025.2538130","DOIUrl":"https://doi.org/10.1080/01616412.2025.2538130","url":null,"abstract":"<p><strong>Objective: </strong>This study examined the therapeutic effects of tramadol hydrochloride and levetiracetam on preventing peridural fibrosis after laminectomy in rats.</p><p><strong>Methods: </strong>Under sedation anesthesia, standard laminectomies at T9, T10, and T11 were performed on 32 male Wistar albino rats weighing 300-350 g. The rats were then divided into groups: Sham (no pharmacological agent administered, <i>n</i> = 6 + 2); MP group (10 mg/kg/day methylprednisolone sodium succinate administered intraperitoneally for 14 days, <i>n</i> = 6 + 2); TRA group (0.6 mg/kg/day tramadol hydrochloride administered intraperitoneally for 14 days, <i>n</i> = 6 + 2); and LEV group (15 mg/kg/day levetiracetam administered intraperitoneally for 14 days, <i>n</i> = 6 + 2). Four weeks after surgery, all animals were euthanized, and their spinal columns were removed en bloc. Peridural fibrosis and collagen density were evaluated using hematoxylin-eosin and Masson-Trichrome staining, respectively. Collagen and alpha-SMA levels were assessed with COL1A1 and ACTA2 staining, respectively. ELISA measurements were taken for TNF-α, IL-6, TGF-ß, CTGF, caspase-3, and GSH/GSSG levels. Western blot analysis was performed to determine pAMPK, mTOR, pmTOR, and mTOR/p-mTOR levels.</p><p><strong>Results: </strong>Histopathological and immunohistochemical analyses showed that methylprednisolone and tramadol reduced peridural fibrosis, collagen density, and collagen formation. Both agents exhibited anti-inflammatory and anti-apoptotic effects by decreasing TNF-α, IL-6, caspase-3, TGF-β, and CTGF levels. They demonstrated antioxidant properties by increasing GSH/GSSG levels, and they supported autophagy by increasing pAMPK and decreasing pmTOR levels.</p><p><strong>Conclusion: </strong>In summary, all three agents possessed anti-inflammatory, antioxidant, anti-apoptotic, and autophagy-associated tissue regenerative properties. Due to these effects, they have the potential to reduce peridural fibrosis in the rat laminectomy model.</p>","PeriodicalId":19131,"journal":{"name":"Neurological Research","volume":" ","pages":"1-17"},"PeriodicalIF":1.7,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of bundle-based preventive care on healthcare-associated infection control in neurosurgical patients.","authors":"Xiaowei Xu, Liqin Wei, Weiwei Wang, Yu Sun, Li Zheng, Yan Wang","doi":"10.1080/01616412.2025.2537329","DOIUrl":"https://doi.org/10.1080/01616412.2025.2537329","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to investigate the effects of bundle-based preventive care on the control of healthcare-associated infections (HAIs) in patients undergoing neurosurgical procedures.</p><p><strong>Methods: </strong>One hundred and twenty patients who underwent neurosurgery were enrolled and randomly assigned, using a random number table method, to either the control group (<i>n</i> = 60), which received routine nursing care, or the observation group (<i>n</i> = 60), which bundle-based preventive care. The incidence of HAIs, antibiotic usage, and pathogen detection rates were compared between the two groups. In addition, adverse events and length of hospital stay were recorded. Nursing quality and patient satisfaction were also evaluated.</p><p><strong>Results: </strong>The observation group showed significantly better outcomes than the control group. Specifically, its HAI rate (6.67% vs. 21.67%) and total pathogen detection rate (6.67% vs. 20.00%) were significantly lower (<i>p</i> < 0.05). The use of dual and triple antibiotic regimens was also reduced (<i>p</i> < 0.05). Moreover, the observation group experienced fewer adverse events and a shorter hospital stay (<i>p</i> < 0.05). Nursing quality scores - including hand hygiene, disinfection and isolation, nursing communication, and documentation - were all higher in the observation group (<i>p</i> < 0.05). Patient satisfaction was significantly improved as well (95.00% vs. 83.33%, <i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>Bundle-based preventive care can effectively reduce postoperative HAIs and antibiotic usage in neurosurgical patients, lower the incidence of adverse events, and significantly improve nursing quality and patient satisfaction.</p>","PeriodicalId":19131,"journal":{"name":"Neurological Research","volume":" ","pages":"1-8"},"PeriodicalIF":1.7,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of levodopa response rate in association with clinical features in Parkinson's disease subjects with and without STN-DBS.","authors":"Halil Onder, Selcuk Comoglu","doi":"10.1080/01616412.2025.2537897","DOIUrl":"https://doi.org/10.1080/01616412.2025.2537897","url":null,"abstract":"<p><strong>Background: </strong>The levodopa response (LR) in patients with deep brain stimulation of the subthalamic nucleus (STN-DBS) has rarely been investigated. We sought to investigate the LR, and clinical features associated with STN-DBS therapy.</p><p><strong>Methods: </strong>PD subjects with and without STN-DBS who applied to our movement disorders outpatient clinics between January 2023 and July 2023 were evaluated. The clinical features and detailed clinical scales, including MDS-UPDRS, FOGQ, FES, VHI, and PDQ-39 were administered. LR was measured by calculating the percent medication-'off' to 'on' change in the MDS-UPDRS-3 scores.</p><p><strong>Results: </strong>Overall, 169 patients with PD participated in this study (35 patients with STN-DBS, and 134 patients without STN-DBS). The mean age of the patients was 60.9 ± 8.8 y (F/M = 66/103), and the disease duration was 7y. The comparative analyses revealed that the disease duration, the MDS-UPDRS-2 and MDS-UPDRS-3 'off' scores were higher in the DBS group. In addition, the scores for axial features such as VHI, FOGQ, and FES-I were higher in the DBS group. However, the LR percentage did not differ between groups (0.47 versus 0.44, <i>p</i> = 0.095). The regression analyses revealed LR rate (B = 5.547, <i>p</i> < 0.01), disease duration (B = 0.349, <i>p</i> < 0.001), and FOGQ (B = 0.175, <i>p</i> < 0.01) as predictors of STN-DBS group.</p><p><strong>Conclusions: </strong>LR was similar between patients with and without STN-DBS, suggesting that non-dopaminergic mechanisms contribute to the efficacy of STN-DBS while underscoring the continued importance of dopaminergic therapy in these patients.</p>","PeriodicalId":19131,"journal":{"name":"Neurological Research","volume":" ","pages":"1-10"},"PeriodicalIF":1.7,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of potential biomarkers and therapeutic targets for cerebral venous thrombosis.","authors":"Jiahao Song, Jingrun Li, Gaolan Zhang, Guangyu Han, Xiaoming Zhang, Xunming Ji, Yuchuan Ding, Da Zhou, Ran Meng","doi":"10.1080/01616412.2025.2532039","DOIUrl":"https://doi.org/10.1080/01616412.2025.2532039","url":null,"abstract":"<p><strong>Background and aims: </strong>Cerebral venous thrombosis (CVT) is an uncommon yet potentially life-threatening subtype of stroke that predominantly affects younger individuals. This study aimed to systematically identify and validate druggable genes associated with CVT susceptibility using Mendelian randomization (MR) approaches.</p><p><strong>Methods: </strong>We integrated two large-scale expression quantitative trait loci (eQTLs) datasets - eQTLGen (peripheral blood) and PsychENCODE (brain tissue) - as exposures, with CVT genome-wide association study (GWAS) summary statistics from FinnGen serving as the outcome. A two-sample MR (TSMR) framework was employed, supported by sensitivity analyses, summary-data-based MR (SMR), and Bayesian colocalization. Functional enrichment, single-cell analyses, drug prediction, and molecular docking were further performed to explore biological relevance and therapeutic potential.</p><p><strong>Results: </strong>TSMR identified 19 candidate genes from blood eQTLs after false discovery rate (FDR) correction; two were excluded due to pleiotropy, leaving 17, among which 10 were supported by SMR and colocalization. An additional nominally significant gene (ZP3) was detected from brain tissue. Of these, IL18, BMPR2, and COMT exhibited the strongest evidence. Functional annotation implicated these genes in cytokine signaling, cellular adhesion, and coagulation pathways. Single-cell RNA sequencing localized their expression mainly to monocytes, dendritic cells, and natural killer cells. Drug repurposing and docking analysis suggested potential inhibitory interactions between IL18 and glucocorticoids/pioglitazone, and between BMPR2 and iloprost.</p><p><strong>Conclusion: </strong>This study reveals novel gene networks potentially involved in CVT pathogenesis and prioritizes IL18, BMPR2, and COMT as promising candidates for future therapeutic development. Nonetheless, these findings are based on genetic inference and require further mechanistic and clinical validation.</p>","PeriodicalId":19131,"journal":{"name":"Neurological Research","volume":" ","pages":"1-15"},"PeriodicalIF":1.7,"publicationDate":"2025-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144668066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction.","authors":"","doi":"10.1080/01616412.2025.2531314","DOIUrl":"https://doi.org/10.1080/01616412.2025.2531314","url":null,"abstract":"","PeriodicalId":19131,"journal":{"name":"Neurological Research","volume":" ","pages":"1"},"PeriodicalIF":1.7,"publicationDate":"2025-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144668056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Screening of biomarkers related to Alzheimer's disease based on construction of a ceRNA regulation network.","authors":"Peng Zhang, Yue Ma","doi":"10.1080/01616412.2025.2529563","DOIUrl":"https://doi.org/10.1080/01616412.2025.2529563","url":null,"abstract":"<p><strong>Purpose: </strong>The study objectives were to construct lncRNA-miRNA-mRNA ceRNA regulation network of Alzheimer's disease (AD) and screen the key biomarkers related to AD.</p><p><strong>Methods: </strong>The gene expression data GSE84422 and GSE101684 were downloaded from the NCBI-GEO databases. The differentially expressed RNAs (DElncRNAs, DEmiRNAs, and DEmRNAs) (DERs) were identified by the limma package in R. Then, the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway on the DEmRNAs were analyzed. Moreover, the lncRNA-miRNA-mRNA ceRNA network of AD was built, the key lncRNAs in the ceRNA network were obtained, and the GO and KEGG analysis of lncRNA target genes were performed.</p><p><strong>Results: </strong>In total, we acquired 557 DEmRNAs, 36 DElncRNAs and 178 DEmiRNAs in AD. We found that the DEmRNAs were significantly associated with immune-related pathways, such as antigen processing and presentation and graft-versus-host disease. Moreover, the ceRNA regulation network of AD was construct. We identified two key up-regulated lncRNAs, including LINC01094 and LINC00092; and ten key down-regulated lncRNAs, such as CH17-264L24.1, LINC01140 and RP11-159D12.2, etc.</p><p><strong>Conclusion: </strong>This research built a ceRNA regulation network of AD, which is of great significance for identifying the biomarkers related to AD.</p>","PeriodicalId":19131,"journal":{"name":"Neurological Research","volume":" ","pages":"1-10"},"PeriodicalIF":1.7,"publicationDate":"2025-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144668068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PSMC3IP as a prognostic biomarker and immunomodulatory regulator in low-grade glioma: insights from multi-omics and methylation analysis.","authors":"Zongye Zhang, Zhi Sha, Hao Wang, Yusheng Chen, Zhendong Liu, Xingbo Cheng, Sujie Gu, Yanzheng Gao","doi":"10.1080/01616412.2025.2528159","DOIUrl":"https://doi.org/10.1080/01616412.2025.2528159","url":null,"abstract":"<p><strong>Objectives: </strong>PSMC3IP, a gene involved in proteasome function, has been linked to various cancers, though its role in low-grade glioma (LGG) remains underexplored. This study investigates its expression and mechanisms in LGG, offering insights into treatment and prognosis evaluation.</p><p><strong>Methods: </strong>Integrate multi-omics data from TCGA, CGGA, and other sources to analyze the association between PSMC3IP expression and clinical features and survival prognosis, and combine methylation analysis, immune infiltration assessment, and GSEA-enriched pathways to elucidate its functional mechanisms.</p><p><strong>Results: </strong>The overexpression of PSMC3IP in LGG was significantly correlated with malignant clinical features, including higher WHO grade, tumor recurrence, and 1p19q co-deletion (<i>p</i> < 0.05). Patients with high PSMC3IP expression exhibited significantly shortened overall survival (<i>p</i> < 0.001). Methylation analysis revealed that the cg12628062 locus negatively regulated PSMC3IP expression (<i>r</i> = -0.22, <i>p</i> < 0.001). Immune microenvironment profiling demonstrated that PSMC3IP overexpression promoted tumor associated macrophages to polarize towards M2 morphology, suppressed CD8+ T cell activity, and elevated expression of immune checkpoints (PDCD1/CTLA-4). Gene Set Enrichment Analysis (GSEA) further highlighted its enrichment in DNA replication and base excision repair pathways, suggesting its oncogenic role through genomic instability and immunomodulatory mechanisms.</p><p><strong>Conclusion: </strong>PSMC3IP is overexpressed in LGG and serves as an independent prognostic factor for poor survival. Its involvement in immune regulation and key molecular pathways, including DNA replication, suggests it may be a target for therapeutic strategies in LGG.</p>","PeriodicalId":19131,"journal":{"name":"Neurological Research","volume":" ","pages":"1-17"},"PeriodicalIF":1.7,"publicationDate":"2025-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144668067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative efficacy and safety of prourokinase versus alteplase for acute ischemic stroke within 4.5 hours: a systematic review and meta-analysis of randomized controlled trials.","authors":"Hazem E Mohammed, Mohamed E Haseeb, Zeyad Bady, Yusra Arafeh","doi":"10.1080/01616412.2025.2533419","DOIUrl":"https://doi.org/10.1080/01616412.2025.2533419","url":null,"abstract":"<p><strong>Background: </strong>Intravenous thrombolysis with recombinant tissue plasminogen activator, such as alteplase, is the standard treatment for acute ischemic stroke (AIS). However, concerns about cost and safety have led to an interest in alternative thrombolytics like prourokinase (rhPro-UK). This meta-analysis evaluated the efficacy and safety of prourokinase compared to alteplase for AIS treatment within 4.5 hours of symptom onset.</p><p><strong>Methods: </strong>A literature search was conducted across PubMed, Web of Science, and Scopus up to January 2025. The outcome measures included functional outcomes (modified Rankin Scale [mRS]), early neurological improvement (NIHSS reduction), and safety outcomes, involving symptomatic intracranial hemorrhage (sICH). PROSPERO registration is CRD42025632210.</p><p><strong>Results: </strong>Three RCTs with a total of 2,289 patients were included. The proportion of patients achieving excellent functional outcomes (mRS 0-1 at 90 days) did not differ significantly between groups (risk ratio (RR): 1.04, 95% confidence interval (CI): 0.98-1.10, <i>p</i> = 0.17). Similarly, good functional outcomes (mRS 0-2) were comparable (<i>p</i> = 0.86). Early neurological improvement at 24 hours was also similar (<i>p</i> = 0.32). However, prourokinase showed a slight but statistically significant advantage in NIHSS score reduction at 24 hours (mean difference (MD): -0.43, 95% CI: -0.85 to -0.02, <i>p</i> = 0.04). The risk of sICH, defined by ECASS III (<i>p</i> = 0.16) and SITS-MOST (<i>p</i> = 0.07), showed insignificant difference.</p><p><strong>Conclusion: </strong>Prourokinase is a safe and effective thrombolytic agent for AIS within 4.5 hours, demonstrating non-inferiority to alteplase in both efficacy and safety. Its advantages, including lower cost and ease of administration, make it a viable alternative. Future large-scale trials are recommended.</p>","PeriodicalId":19131,"journal":{"name":"Neurological Research","volume":" ","pages":"1-12"},"PeriodicalIF":1.7,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144643036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}